Does Beauty Farm Medical and Health Industry (HKG:2373) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage to find investors. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. Loss-making companies are always racing against time to reach financial sustainability, so investors in these companies may be taking on more risk than they should.
In contrast to all that, many investors prefer to focus on companies like Beauty Farm Medical and Health Industry (HKG:2373), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Beauty Farm Medical and Health Industry with the means to add long-term value to shareholders.
Beauty Farm Medical and Health Industry's Earnings Per Share Are Growing
Generally, companies experiencing growth in earnings per share (EPS) should see similar trends in share price. Therefore, there are plenty of investors who like to buy shares in companies that are growing EPS. Impressively, Beauty Farm Medical and Health Industry has grown EPS by 18% per year, compound, in the last three years. As a general rule, we'd say that if a company can keep up that sort of growth, shareholders will be beaming.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. The music to the ears of Beauty Farm Medical and Health Industry shareholders is that EBIT margins have grown from 13% to 16% in the last 12 months and revenues are on an upwards trend as well. Ticking those two boxes is a good sign of growth, in our book.
In the chart below, you can see how the company has grown earnings and revenue, over time. To see the actual numbers, click on the chart.
View our latest analysis for Beauty Farm Medical and Health Industry
Fortunately, we've got access to analyst forecasts of Beauty Farm Medical and Health Industry's future profits. You can do your own forecasts without looking, or you can take a peek at what the professionals are predicting.
Are Beauty Farm Medical and Health Industry Insiders Aligned With All Shareholders?
Insider interest in a company always sparks a bit of intrigue and many investors are on the lookout for companies where insiders are putting their money where their mouth is. That's because insider buying often indicates that those closest to the company have confidence that the share price will perform well. Of course, we can never be sure what insiders are thinking, we can only judge their actions.
The real kicker here is that Beauty Farm Medical and Health Industry insiders spent a staggering CN¥7.4m on acquiring shares in just one year, without single share being sold in the meantime. Buying like that is a fantastic look for the company and should rouse the market in anticipation for the future. It is also worth noting that it was Non-Executive Director Fangyu Li who made the biggest single purchase, worth HK$1.4m, paying HK$26.17 per share.
Along with the insider buying, another encouraging sign for Beauty Farm Medical and Health Industry is that insiders, as a group, have a considerable shareholding. We note that their impressive stake in the company is worth CN¥1.5b. That equates to 32% of the company, making insiders powerful and aligned with other shareholders. Very encouraging.
While insiders already own a significant amount of shares, and they have been buying more, the good news for ordinary shareholders does not stop there. That's because on our analysis the CEO, Songyong Lian, is paid less than the median for similar sized companies. Our analysis has discovered that the median total compensation for the CEOs of companies like Beauty Farm Medical and Health Industry with market caps between CN¥1.3b and CN¥5.4b is about CN¥2.6m.
Beauty Farm Medical and Health Industry offered total compensation worth CN¥2.2m to its CEO in the year to December 2025. That comes in below the average for similar sized companies and seems pretty reasonable. CEO remuneration levels are not the most important metric for investors, but when the pay is modest, that does support enhanced alignment between the CEO and the ordinary shareholders. Generally, arguments can be made that reasonable pay levels attest to good decision-making.
Does Beauty Farm Medical and Health Industry Deserve A Spot On Your Watchlist?
For growth investors, Beauty Farm Medical and Health Industry's raw rate of earnings growth is a beacon in the night. Not only that, but we can see that insiders both own a lot of, and are buying more shares in the company. So it's fair to say that this stock may well deserve a spot on your watchlist. It is worth noting though that we have found 1 warning sign for Beauty Farm Medical and Health Industry that you need to take into consideration.
Keen growth investors love to see insider activity. Thankfully, Beauty Farm Medical and Health Industry isn't the only one. You can see a a curated list of Hong Kong companies which have exhibited consistent growth accompanied by high insider ownership.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.